Cara Therapeutics Q1 2024 GAAP EPS $(0.56) Misses $(0.40) Estimate, Sales $2.135M Beat $1.690M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cara Therapeutics reported Q1 2024 GAAP EPS of $(0.56), missing the $(0.40) estimate, but their sales of $2.135M exceeded the $1.690M estimate. This represents a significant decrease in sales compared to the same period last year.
May 13, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cara Therapeutics missed EPS estimates but exceeded sales forecasts for Q1 2024, with a notable decrease in sales year-over-year.
Missing the EPS estimate by 40% is likely to negatively impact investor sentiment and stock price in the short term. However, beating sales estimates might offset some of the negative impact. The significant year-over-year sales decrease is a critical factor that could further dampen investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100